Compare Boston Scientific Corporation (BSX) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs SOLAI Limited — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while SOLAI Limited trades at $3.14 (market cap $14.09M). The key difference: Boston Scientific Corporation is far larger — about 4710.4× SOLAI Limited's market cap. Which is the better fit depends on your goals.
| BSX | SLAI | |
|---|---|---|
Market Cap | $66.37B | $14.09M |
Sector | Health | Technology |
52-Week High | $108.14 | $30.66 |
52-Week Low | $42.63 | $2.74 |
Enterprise Value | $75.94B | $13.72M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
SLAI trades at $3.24, down 2.99% today, with a bullish technical signal supported by moving averages. The company shows concerning fundamentals with negative gross profit margin of -44.87% and net income margin of -134.63% for 2025. Recent developments include the acquisition of a 51% stake in NEURALAND and the launch of Solode Neo AI device. The stock faces NYSE listing standard concerns but shows improved revenue guidance for 2026.
The outlook remains challenged by persistent losses and regulatory risks, though recent acquisitions and product launches offer potential growth catalysts. Investors face significant execution risk amid negative profitability metrics, while technical indicators suggest near-term price support around $3 with resistance at $4.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
